Background: Angiotensin II (Ang II) and the renal sympathetic nervous system exert a strong influence on renal sodium and water excretion. We tested the hypothesis that already low doses of an Ang II inhibitor (candesartan) will result in similar effects on tubular sodium and water reabsorption in congestive heart failure (CHF) as seen after renal denervation (DNX).
Methods: Measurement of arterial blood pressure, heart rate (HR), renal sympathetic nerve activity (RSNA), glomerular filtration rate (GFR), renal plasma flow (RPF), urine volume, and urinary sodium. To assess neural control of volume homeostasis, 21 days after the induction of CHF via myocardial infarction rats underwent volume expansion (0.9% NaCL; 10% body weight) to decrease RSNA. CHF rat and controls with or without DNX or pretreated with the Ang II type-1 receptor antagonist candesartan (0.5 ug i.v.) were studied.
Results: CHF rats excreted only 68 + 10.2% of the volume load (10% body weight) in 90 min. CHF rats pretreated with candesartan or after DNX excreted from 92 to 103% like controls. Decreases of RSNA induced by volume expansion were impaired in CHF rats but unaffected by candesartan pointing to an intrarenal drug effect. GFR and RPF were not significantly different in controls or CHF.
Conclusion: The prominent function of increased RSNA - retaining salt and water - could no longer be observed after renal Ang II receptor blockade in CHF rats.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1159/000515616 | DOI Listing |
J Gene Med
January 2025
Shanghai University of Traditional Chinese Medicine, Longhua Hospital, Shanghai, China.
Cardiac dysfunction and adverse consequences induced by cardiac fibrosis have been well documented. However, the cardiac fibrosis pathway in chronic heart failure (CHF) remains unclear, and it is therefore necessary to conduct further research for the sake of developing more effective therapeutic strategies for CHF. Some recent studies suggest that Pericarpium Trichosanthis (PT) may help improve the progression of fibrotic diseases.
View Article and Find Full Text PDFBiomed Chromatogr
February 2025
Department of Pharmacy, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou, China.
The high mortality rate of chronic heart failure (CHF) makes it a primary battlefield in the field of cardiovascular diseases. Qiangxin Lishui Prescription (QLP) is a traditional Chinese medicine (TCM) prescription used clinically for treating CHF, but its underlying mechanism remains unclear. This study integrated plasma metabolomics, network pharmacology, and experimental validation to reveal the pharmacological effects of QLP and its potential mechanism of anti-CHF.
View Article and Find Full Text PDFFront Biosci (Landmark Ed)
December 2024
Department of Cardiovascular Medicine, The Affiliated Changsha Hospital of Xiangya School of Medicine, Central South University, 410008 Changsha, Hunan, China.
Background: Chronic heart failure (CHF) is a serious cardiovascular condition. Vascular peroxidase 1 (VPO1) is associated with various cardiovascular diseases, yet its role in CHF remains unclear. This research aims to explore the involvement of VPO1 in CHF.
View Article and Find Full Text PDFIndian J Pharmacol
September 2024
Department of Pharmacology, Seth GS Medical College and KEM Hospital, Mumbai, Maharashtra, India.
Objectives: The development and progression of chronic heart failure (CHF), hypertrophy, and remodeling strongly correlate with myocardial inflammation and oxidative stress. S-adenosylmethionine (SAMe), available as a dietary supplement, exerts anti-inflammatory and antioxidant effects. Previous reports show that by regulating angiogenesis and fibrosis, S-adenosyl-L-methionine improves ventricular remodeling.
View Article and Find Full Text PDFNutrients
November 2024
Department of Food Science, College of Life Science, National Taiwan Ocean University, Keelung 20224, Taiwan.
Background/objectives: Although high-fat, low-carbohydrate diets are used for weight loss and type 2 diabetes management, their high-fat content may have negative effects. This study examines the effects of replacing cellulose with chitosan and part of the fat with fish oil in a high-fat, low-carbohydrate diet on lipid metabolism in rats.
Methods: The experiment involved 35 six-week-old male SD rats, divided into five groups: normal control diet (ND), high-fat diet (HF), high-fat, low-carbohydrate diet (LC), LC with 5% chitosan (LC-CH), and LC with 5% chitosan and 5% fish oil (LC-CHF).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!